🇺🇸 FDA
Patent

US 9782399

Pharmaceutical compositions which inhibit FKBP52-mediated regulation of androgen receptor function and methods of using same

granted A61KA61K31/165A61K31/167

Quick answer

US patent 9782399 (Pharmaceutical compositions which inhibit FKBP52-mediated regulation of androgen receptor function and methods of using same) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Oct 05 2037 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Secretary, Department of Health and Human Services
Grant date
Tue Oct 10 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Oct 05 2037 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
19
CPC classes
A61K, A61K31/165, A61K31/167, A61K31/192, A61K31/195